TY - CHAP M1 - Book, Section TI - Treatment of Pulmonary Arterial Hypertension A1 - Fraidenburg, Dustin R. A1 - Desai, Ankit A. A1 - Makino, Ayako A1 - Yuan, Jason X.-J. A2 - Brunton, Laurence L. A2 - Knollmann, Björn C. Y1 - 2023 N1 - T2 - Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition AB - AbbreviationsBCRP: breast cancer resistance proteinBNP: B-type natriuretic peptide[Ca2+]cyt: cytosolic free Ca2+ concentrationCCB: calcium channel blockerCTEPH: chronic thromboembolic pulmonary hypertensionCYP: cytochrome P450DAG: diacylglycerolEC: endothelial cellECE: endothelin-converting enzymeEGF: epidermal growth factorER: endoplasmic reticulumERA: endothelin receptor antagonistET-1: endothelin 1FDA: U.S. Food and Drug AdministrationGPCR: G protein-coupled receptorIP3: inositol triphosphateIPR: prostacyclin receptormGC: membrane (or particulate) guanylate cyclaseNO: nitric oxideNO2: nitric dioxidePA: pulmonary arteryPAH: pulmonary arterial hypertensionPAP: pulmonary arterial pressurePASMC: pulmonary artery smooth muscle cellPDE: phosphodiesterasePDGF: platelet-derived growth factorPGI2: prostacyclin, prostaglandin I2Pgp : P-glycoproteinPH: pulmonary hypertensionPKA: protein kinase APKC: protein kinase CPKG: protein kinase GPLC: phospholipase CPVR: pulmonary vascular resistanceREMS: Risk Evaluation and Mitigation StrategyROC: receptor-operated Ca2+ channelRV: right ventriclesGC: soluble guanylate cyclaseSR: sarcoplasmic reticulumSVR: systemic vascular resistanceTGF-β: transforming growth factor-βTKR: tyrosine kinase receptorVDCC: voltage-dependent Ca2+ channelVEGF: vascular endothelial growth factorVIP: vasoactive intestinal peptideV/Q: ventilation/perfusionVSM: vascular smooth muscle SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193233420 ER -